Takeuchi, H, Suzuki, T, Uchida, H, Watanabe, K, Mimura, M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res
2012; 134: 219–25.
Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Salanti, G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet
2012; 379: 2063–71.
Gleeson, JFM, Alvarez-Jimenez, M, Cotton, SM, Parker, AG, Hetrick, S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res
2010; 119: 79–88.
Kishimoto, T, Agarwal, V, Kishi, T, Leucht, S, Kane, JM, Correll, CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry
2013; 18: 53–66.
Kishimoto, T, Robenzadeh, A, Leucht, C, Leucht, S, Watanabe, K, Mimura, M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull
2014; 40: 192–213.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Overall, JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychol Rep
1962; 10: 799–812.
Agid, O, Kapur, S, Arenovich, T, Zipursky, RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry
2003; 60: 1228–35.
Sherwood, M, Thornton, AE, Honer, WG. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. Int J Neuropsychopharmacol
2006; 9: 357–66.
Suzuki, T, Remington, G, Arenovich, T, Uchida, H, Agid, O, Graff-Guerrero, A, et al. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry
2011; 199: 275–80.
Sherwood, M, Thornton, AE, Honer, WG. A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine. J Psychopharmacol
2012; 26: 1175–84.
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ
2009; 339: b2535.
Higgins, JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions.
The Cochrane Collaboration, 2011 (http://handbook.cochrane.org).
Leucht, S, Davis, JM, Engel, RR, Kane, JM, Wagenpfeil, S. Defining ‘response’ in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology
2007; 32: 1903–10.
Obermeier, M, Mayr, A, Schennach-Wolff, R, Seemüller, F, Möller, H-J, Riedel, M. Should the PANSS be rescaled?
2010; 36: 455–60.
Leucht, S, Kissling, W, Davis, JM. The PANSS should be rescaled. Schizophr Bull
2010; 36: 461–2.
Furukawa, TA, Levine, SZ, Tanaka, S, Goldberg, Y, Samara, M, Davis, JM, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry
2015; 72: 14–21.
Arato, M, O'Connor, R, Meltzer, HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol
2002; 17: 207–15.
Beasley, CM, Sutton, VK, Hamilton, SH, Walker, DJ, Dossenbach, M, Taylor, CC, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol
2003; 23: 582–94.
Clark, ML, Huber, WK, Hill, D, Wood, F, Costiloe, JP. Pimozide in chronic schizophrenic outpatients. Dis Nerv Syst
1975; 36: 137–41.
Cooper, SJ, Butler, A, Tweed, J, Welch, C, Raniwalla, J. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology (Berl)
2000; 150: 237–43.
Fu, D-J, Turkoz, I, Simonson, RB, Walling, DP, Schooler, NR, Lindenmayer, J-P, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry
2015; 76: 253–62.
Hough, D, Gopal, S, Vijapurkar, U, Lim, P, Morozova, M, Eerdekens, M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res
2010; 116: 107–17.
Kane, JM, Sanchez, R, Perry, PP, Jin, N, Johnson, BR, Forbes, RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry
2012; 73: 617–24.
Kramer, M, Simpson, G, Maciulis, V, Kushner, S, Vijapurkar, U, Lim, P, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol
2007; 27: 6–14.
Pigott, TA, Carson, WH, Saha, AR, Torbeyns, AF, Stock, EG, Ingenito, GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry
2003; 64: 1048–56.
Rui, Q, Wang, Y, Liang, S, Liu, Y, Wu, Y, Wu, Q, et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry
2014; 53C: 45–53.
Tandon, R, Cucchiaro, J, Phillips, D, Hernandez, D, Mao, Y, Pikalov, A, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol
2016; 30: 69–77.
Gitlin, M, Nuechterlein, K, Subotnik, KL, Ventura, J, Mintz, J, Fogelson, DL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry
2001; 158: 1835–42.
Zipursky, RB, Menezes, NM, Streiner, DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res
2014; 152: 408–14.
Mayoral-van Son, J, de la Foz, VO-G, Martinez-Garcia, O, Moreno, T, Parrilla-Escobar, M, Valdizan, EM, et al. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals. J Clin Psychiatry
2016; 77: 492–500.
Harrow, M, Jobe, TH, Faull, RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med
2012; 42: 2145–55.
Moilanen, J, Haapea, M, Miettunen, J, Jääskeläinen, E, Veijola, J, Isohanni, M, et al. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication – a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry
2013; 28: 53–8.
Wils, RS, Gotfredsen, DR, Hjorth⊘j, C, Austin, SF, Albert, N, Secher, RG, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res
2017; 182: 42–8.
Inderbitzin, LB, Lewine, RR, Scheller-Gilkey, G, Swofford, CD, Egan, GJ, Gloersen, BA, et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am J Psychiatry
1994; 151: 1753–9.
Takeuchi, H, Suzuki, T, Remington, G, Bies, RR, Abe, T, Graff-Guerrero, A, et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull
2013; 39: 993–8.
Viguera, AC, Baldessarini, RJ, Hegarty, JD, van Kammen, DP, Tohen, M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry
1997; 54: 49–55.
Leucht, S, Kane, JM, Kissling, W, Hamann, J, Etschel, E, Engel, RR. What does the PANSS mean?
2005; 79: 231–8.
Murray, RM, Quattrone, D, Natesan, S, van Os, J, Nordentoft, M, Howes, O, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Br J Psychiatry
2016; 209: 361–5.
Wunderink, L, Nieboer, RM, Wiersma, D, Sytema, S, Nienhuis, FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry
2013; 70: 913–20.
Wunderink, L, Nienhuis, FJ, Sytema, S, Slooff, CJ, Knegtering, R, Wiersma, D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry
2007; 68: 654–61.
Jaaskelainen, E, Juola, P, Hirvonen, N, McGrath, JJ, Saha, S, Isohanni, M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull
2013; 39: 1296–306.
Harrow, M, Jobe, TH. Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?
2013; 39: 962–5.